Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755867 · ClinicalTrials.gov registry record
Global PNH Patient Registry
A clinical trial of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Aplastic Anemia and MDS International Foundation.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05755867: Recruiting study of Paroxysmal Nocturnal Hemoglobinuria, sponsored by Aplastic Anemia and MDS International Foundation.
NCT05755867 is a study of Paroxysmal Nocturnal Hemoglobinuria that is actively recruiting participants, run by Aplastic Anemia and MDS International Foundation. The registered enrollment target is 500 participants, above the 229-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (118% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05755867, a study of Paroxysmal Nocturnal Hemoglobinuria, is actively recruiting participants, sponsored by Aplastic Anemia and MDS International Foundation.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry is to conduct a prospectively-planned and efficient natural history study that will result in a more comprehensive understanding of the disease and its course and pace over time. Other registry objectives include the following: * Provide a convenient online platform for participants (or caregivers) to self-report cases of PNH. * Develop a communications registry within the Global PNH Patient registry (e.g., to notify patients of research studies and clinical trials). * Characterize and describe the Global PNH population as a whole, enhancing the understanding of disease prevalence and phenotype as well as the rate of progression of disease characteristics. * Assist the PNH community with the development of recommendations and standards of care. * Be a case-finding resource to be used for researchers who seek to study the pathophysiology of PNH, retrospectively collate intervention outcomes, and design prospective trials of novel treatments.
Primary Outcome
Understand disease prevalence and phenotype as well as the rate of progression of disease characteristics. Gather patient experiences including demographics, diagnostics, treatment, symptoms, and quality of life.
Conditions Studied
Study Locations (1)
Maryland
- Aplastic Anemia and MDS International Foundation - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2031-05-06 |
What NCT05755867 shows while recruiting
NCT05755867 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 229-participant average among 14 other Paroxysmal Nocturnal Hemoglobinuria trials with a reported enrollment target (118% higher).
The record links to 1 condition, with Paroxysmal Nocturnal Hemoglobinuria appearing as the primary indexed condition, and to 0 interventions.
NCT05755867 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05755867 about?
NCT05755867 is a clinical study titled "Global PNH Patient Registry". The primary aim of the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry is to conduct a prospectively-planned and efficient natural history study that will result in a more comprehensive understanding of the disease and its course and pace over time. Other registry objectives includ...
What is the current status of trial NCT05755867?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-05-06. Estimated completion is 2031-05-06.
What conditions does trial NCT05755867 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria.
Who is sponsoring clinical trial NCT05755867?
This trial is sponsored by Aplastic Anemia and MDS International Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05755867 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05755867's enrollment target sits among peer trials
500 2nd of 14 the highest of 14 other Paroxysmal Nocturnal Hemoglobinuria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Nocturnal Hemoglobinuria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The International PNH Interest Group PNH Registry
RECRUITING
-
Home Reported Outcomes in PNH
RECRUITING
-
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
RECRUITING · Phase 3
-
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
RECRUITING · Phase 2
-
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
ACTIVE NOT RECRUITING
-
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI